Dermata Therapeutics Inc (DRMA)vsModerna Inc (MRNA)
DRMA
Dermata Therapeutics Inc
$1.46
-9.32%
HEALTHCARE · Cap: $5.91M
MRNA
Moderna Inc
$142.77
-4.60%
HEALTHCARE · Cap: $57.00B
Smart Verdict
WallStSmart Research — data-driven comparison
DRMA leads profitability with a 0.0% profit margin vs -141.4%. DRMA earns a higher WallStSmart Score of 23/100 (F).
DRMA
Avoid23
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DRMA.
Margin of Safety
+70.0%
Fair Value
$135.25
Current Price
$142.77
$7.52 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DRMA
The strongest argument for DRMA centers on Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : DRMA
The primary concerns for DRMA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
DRMA profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 0.90 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
DRMA generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
DRMA scores higher overall (23/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dermata Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for dermatological conditions, particularly through its lead candidate, DMT310. Utilizing a proprietary delivery system, DMT310 seeks to enhance the efficacy of existing acne treatments while addressing significant unmet needs within the dermatology space. With a robust pipeline and a commitment to pioneering dermatological solutions, Dermata Therapeutics is positioned to make a meaningful impact on skin health and improve patient outcomes. As the company advances in its clinical trials, it holds the potential to become a disruptive player in the treatment of skin disorders.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?